[Baili Tianheng: The marketing application for Yizekang® to treat HR+HER2-breast cancer was accepted] On October 22, Baili Tianheng (688506.SH) announced that the company received the "Acceptance Notice" approved and issued by the Drug Evaluation Center of the State Food and Drug Administration, and independently developed The drug marketing application of the world's first dual-antibody ADC drug Yizekang® (Lunkang ilontumumab) for the treatment of unresectable or metastatic HR+HER2- breast cancer that has previously received endocrine therapy and received at least first-line chemotherapy in the advanced disease stage has been officially accepted. The application is based on the interim analysis results of the Phase III clinical trial and is the world's first Phase III clinical study of a dual anti-ADC drug to achieve the primary endpoint in the treatment of HR+HER2- breast cancer. Up to now, Yizekang® has been approved for marketing for 2 indications, and NDA has been accepted for 2 other indications.